Cargando…
The use of bevacizumab in primary malignant tumors of the central nervous system: A single-center experience
Primary central nervous system tumors rank 8 among other cancers in patients over 40 years of age. Glioblastoma is the most common primary central nervous system malignancy, accounting for 48 percent of the cases. The present study evaluates the effect of bevacizumab on the disease course in patient...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378976/ https://www.ncbi.nlm.nih.gov/pubmed/37505182 http://dx.doi.org/10.1097/MD.0000000000034286 |